Skip to main content

ATS 2024 Sanofi | Regeneron | May 17, 2024 - May 22, 2024

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.

  • COPD

  • NOTUS late-breaker

  • COPD continued